Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies.
about
Specific in vivo knockdown of protein function by intrabodiesIntrabodies as neuroprotective therapeuticsIBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CAESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo.Differential nuclear localization of complexes may underlie in vivo intrabody efficacy in Huntington's disease.NaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies.Bifunctional Anti-Non-Amyloid Component α-Synuclein Nanobodies Are Protective In Situ.Single domain antibodies for the knockdown of cytosolic and nuclear proteins.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CAGene-based antibody strategies for prion diseases.Single-chain fragment variable passive immunotherapies for neurodegenerative diseases.Determination of cell uptake pathways for tumor inhibitor lysyl oxidase propeptide.Recombinant Antibody Fragments for Neurodegenerative Diseases.New Therapeutic Strategies for Lewy Body Dementias.Intracellular Crosslinking of Filoviral Nucleoproteins with Xintrabodies Restricts Viral Packaging.Modifications of a signal sequence for antibody secretion from insect cells.Nanobodies and their potential applications.Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals.Targeted Intracellular Delivery of Antibodies: The State of the ArtProteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model
P2860
Q26801077-20ACEEFC-DE0B-4708-9A38-297EE486FEF5Q27003896-9EDDCF07-202E-448E-B27E-7310018E0892Q28660580-1C19127B-B7F4-466E-BBAB-9661544283DEQ30650119-CFD291A6-19C9-400F-B17B-002764762421Q34313192-4C58E0B8-7CD1-4490-97AA-35F1E33C11FAQ36081897-0E408A7A-71AD-457E-A338-F4DCF58A42AEQ36185625-A8EC53CB-0567-46F7-A6C5-91721B72E81DQ36300378-AE84F603-CD18-43F1-B051-0F00B7E15D01Q36484413-4D3657CD-E5B8-42B8-A6F1-0AF6D0D749F7Q37397677-CC3210B2-F69D-4B2B-BD9E-6521BA7B0618Q38136658-86CF26B4-16DD-4A2E-9B32-1B2D191F6BE9Q38139218-9CE16505-4225-4C9D-900D-B6A382BFE1B5Q38841862-9E387B09-E2D7-4A02-B698-146A7FECB818Q38970823-F7D16D2B-5FF4-4BAB-B39F-7585BA495B65Q39456457-D3A089D3-1FCF-4425-963D-DBD0C6AD19A8Q41918644-7597E8F0-619F-4EEE-9981-FE7AF5A42076Q41986713-3BC3BF4B-E0B8-4916-A2AF-26B4FBBFF7F1Q43682059-BF4E3E19-6A6D-45FB-ACBC-E4AB836500E7Q54943679-B777BF45-628F-4676-8068-39282B182DBBQ58566968-11101615-DC89-4D20-96EC-F033FDFD5371Q58722552-D40B46EB-ACDD-4982-A7B9-2EB80D145D83
P2860
Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Fusion to a highly charged pro ...... se anti-synuclein intrabodies.
@en
Fusion to a highly charged pro ...... se anti-synuclein intrabodies.
@nl
type
label
Fusion to a highly charged pro ...... se anti-synuclein intrabodies.
@en
Fusion to a highly charged pro ...... se anti-synuclein intrabodies.
@nl
prefLabel
Fusion to a highly charged pro ...... se anti-synuclein intrabodies.
@en
Fusion to a highly charged pro ...... se anti-synuclein intrabodies.
@nl
P2093
P2860
P356
P1476
Fusion to a highly charged pro ...... se anti-synuclein intrabodies.
@en
P2093
Anne Messer
David C Butler
Shubhada N Joshi
P2860
P304
P356
10.4161/MABS.21696
P577
2012-08-28T00:00:00Z